STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #208 by analyst upside · 2026-06-27
TVRD
Tvardi Therapeutics, Inc.
Healthcare · Market Cap $14M · P/E 0x
ANALYST PRICE TARGET
+452.4%
implied upside to consensus target
Current Price $1.5
Consensus Target $8.29
Bull Target $15.0
Bear Target $3.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
4
Sell
0
52-Week Low $1.5
52-Week High $43.65
YTD Return -63.2%
FUNDAMENTALS
Market Cap $14M
P/E Ratio (TTM) N/A
Forward P/E -0.5x
EPS (TTM) $-0.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.5
52-Week High $43.65
Current Price $1.5
Bear Target $3.0
Bull Target $15.0
● Now $1.5 ● Target $8.29
TRADING DATA
Avg Volume 83K
YTD Return -63.2%
Analyst Count 7
Consensus Buy
Upside to Target +452.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Tvardi Therapeutics, Inc. (TVRD) is currently trading at $1.5 with a Wall Street consensus price target of $8.29, implying potential upside of 452.4% over the next 12 months. 7 analysts currently cover TVRD, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $3.0.

TVRD operates in the Healthcare sector with a market capitalisation of $14M. The stock is down 63.2% year-to-date and is currently trading near the lower end of its 52-week range of $1.5 – $43.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TVRD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2026-06-08 31% win rate (48 calls)
Barclays ↓ Downgrade
Equal-Weight → Underweight 2026-04-20 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-04-01 Building track record
Piper Sandler — Reiterated
Neutral → Neutral 2026-04-01 14% win rate (7 calls)
BTIG reit
Buy → Buy 2026-04-01 38% win rate (8 calls)
Raymond James ↓ Downgrade
Outperform → Market Perform 2025-10-14 Building track record
BTIG — Reiterated
Buy → Buy 2025-10-13 38% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-10-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
23
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →